Serum CGRP in migraine patients using erenumab as preventive treatment

Simone de Vries Lentsch, Ingrid M. Garrelds, A. H.Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

AIM: Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. METHODS: Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. RESULTS: Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24). CONCLUSION: Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.

Original languageEnglish
Article number120
JournalThe journal of headache and pain
Volume23
Issue number1
DOIs
Publication statusPublished - 12 Sep 2022

Bibliographical note

Funding
This study was supported by Vici grant 09150181910040 from the Dutch Research Council (AMVDB).

Publisher Copyright: © 2022. The Author(s).

Fingerprint

Dive into the research topics of 'Serum CGRP in migraine patients using erenumab as preventive treatment'. Together they form a unique fingerprint.

Cite this